Onderneming HighTide Therapeutics, Inc.
Aandelen
2511
KYG4568L1023
Biotechnologie & Medisch Onderzoek
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
5,84 HKD | -3,95% | -15,36% | -54,94% |
Vakgebied
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Li Ping Liu
CEO | Chief Executive Officer | 55 | 01-01-11 |
Koon Yin Sim
DFI | Director of Finance/CFO | 55 | 01-12-22 |
Cathryn Bennett
CTO | Chief Tech/Sci/R&D Officer | - | - |
Meng Yu
BRD | Director/Board Member | 42 | 04-05-15 |
Ru Bai
PRN | Corporate Officer/Principal | 39 | 06-02-12 |
Li Yu
SEC | Corporate Secretary | 48 | 28-02-18 |
Tian Wei Ma
PRN | Corporate Officer/Principal | 57 | 01-02-23 |
Pik Man Chu
SEC | Corporate Secretary | 27 | 11/12 |
Corporate Officer/Principal | 58 | 01-02-21 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Bo Tan
BRD | Director/Board Member | 51 | - |
Xun Zhu
BRD | Director/Board Member | 66 | 30-11-20 |
Jin Li
BRD | Director/Board Member | 59 | - |
Li Ping Liu
CEO | Chief Executive Officer | 55 | 01-01-11 |
Meng Yu
BRD | Director/Board Member | 42 | 04-05-15 |
Li Xiong Ma
BRD | Director/Board Member | 50 | 16-11-21 |
Feng Jiang
BRD | Director/Board Member | 45 | 16-11-22 |
Tak Wai Hung
BRD | Director/Board Member | 66 | - |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 514 770 668 | 61 698 382 ( 11,99 %) | 41 949 294 ( 8,149 %) | 11,99 % |
Bedrijfsgegevens
Hightide Therapeutics, Inc.
18B-102, Zhonghaixin Innovation Ganli 2nd Road, Jihua Neighborhood
518112, Shenzhen
+
http://www.hightidetx.comSector
Herzieningen van WPA
Winst van het jaar - Afwijkingspercentage
Vaira. 1 jan. | Kapi. | |
---|---|---|
-54,94% | 401 mln. | |
+10,67% | 115 mld. | |
+12,74% | 106 mld. | |
-4,61% | 24,69 mld. | |
-2,33% | 21,97 mld. | |
-6,03% | 19,27 mld. | |
-11,03% | 17,56 mld. | |
-39,36% | 17,32 mld. | |
+6,65% | 14,03 mld. | |
+32,57% | 12,13 mld. |
- Beurs
- Aandelen
- Koers 2511
- Onderneming HighTide Therapeutics, Inc.